Novo Nordisk announced the main clinical trial results of Reimagine 2. Novo Cagrisema demonstrated a weight loss effect of up to 14.2%. Cagrisema shows better weight loss effects compared to SemaglutideWallstreetcn·Feb 2 at 09:45 AM688710+0.58%159859+1.32%
AI healthcare and AI pharmaceutical concepts are experiencing volatile adjustments, with PR falling over 18%, R&G Pharma down nearly 15%, and IMIC, BOJI CRO, GOODWILL, and Berry Genomics all dropping more than 5%Wallstreetcn·Jan 14 at 07:50 PM301230+8.38%301333+3.35%
R&G Pharma released its performance for the first three quarters, with a net profit attributable to the parent company of 95.5668 million yuan, an increase of 13.21%Zhitong·Oct 28, 2025 at 05:05 AM301333+3.35%
R&G Pharma plans to launch an employee stock ownership plan in 2025 with a total funding not exceeding 15 million yuanZhitong·Sep 5, 2025 at 06:20 AM301333+3.35%
R&G Pharma: Net profit of 61.1161 million yuan in the first half of 2025, a year-on-year increase of 4.45%Zhitong·Aug 27, 2025 at 06:13 AM301333+3.35%
R&G Pharma: Has repurchased 1.442 million shares with a total fund amount of 56.0627 million yuanZhitong·Jun 30, 2025 at 06:21 AM301333+3.35%
R&G Pharma: During the company's IPO application process in 2020, it encountered malicious extortionZhitong·Jun 19, 2025 at 12:31 AM301333+3.35%
R&G Pharma statement: False reports affect corporate imageZhitong·Jun 18, 2025 at 08:28 PM301333+3.35%
R&G Pharma: Progress of lawsuits involving the company, its subsidiaries, and actual controllersZhitong·Jun 18, 2025 at 03:04 AM301333+3.35%
The CRO concept saw a short-term surge, with HC CHEMICAL hitting the limit up, and Kingchem, ChemPartner, R&G Pharma, Highfine, and Sino Biological all risingZhitong·May 20, 2025 at 08:49 PM301047+0.72%000953+2.65%
R&G Pharma released its first-quarter performance, with a net profit attributable to the parent company of 26.0737 million yuan, an increase of 13.12%Zhitong·Apr 27, 2025 at 02:49 AM301333+3.35%
The innovative drug concept is repeatedly active, and BHC has hit the daily limitZhitong·Mar 27, 2025 at 08:53 PM688197+1.26%688068+4.55%
R&G Pharma released its 2024 annual performance, with a net profit attributable to the parent company of 140 million yuan, a decrease of 13.73%Zhitong·Mar 27, 2025 at 05:07 AM301333+3.35%
R&G Pharma shareholders HeXie ChengZhang Phase II and HeXie KangJian have cumulatively reduced their holdings by 2.1262 million sharesZhitong·Mar 6, 2025 at 08:19 AM301333+3.35%
